[go: up one dir, main page]

AR126195A1 - Composiciones farmacéuticas de un inhibidor del receptor del factor de crecimiento epidérmico - Google Patents

Composiciones farmacéuticas de un inhibidor del receptor del factor de crecimiento epidérmico

Info

Publication number
AR126195A1
AR126195A1 ARP220101626A ARP220101626A AR126195A1 AR 126195 A1 AR126195 A1 AR 126195A1 AR P220101626 A ARP220101626 A AR P220101626A AR P220101626 A ARP220101626 A AR P220101626A AR 126195 A1 AR126195 A1 AR 126195A1
Authority
AR
Argentina
Prior art keywords
pharmaceutically acceptable
surfactant
compound
solid dispersion
amorphous solid
Prior art date
Application number
ARP220101626A
Other languages
English (en)
Inventor
Caitlin N Mazaik Debra L Medendorp Clare Aubrey Vaze Onkar Shripad Kinkema
Original Assignee
Blueprint Medicines Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blueprint Medicines Corp filed Critical Blueprint Medicines Corp
Publication of AR126195A1 publication Critical patent/AR126195A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente divulgación se refiere a composiciones farmacéuticas que comprenden una fase intragranular, donde la fase intragranular comprende: (I) una dispersión sólida amorfa que comprende el compuesto de fórmula (1) o una sal farmacéuticamente aceptable de este, y un polímero farmacéuticamente aceptable, y (II) un tensioactivo; y una fase extragranular, donde la fase extragranular comprende un tensioactivo. La presente divulgación también se refiere a métodos de utilizar dichos compuestos en el tratamiento de varios trastornos. Reivindicación 1: Una composición farmacéutica caracterizada porque comprende: una fase intragranular, donde la fase intragranular comprende: (i) una dispersión sólida amorfa que comprende el compuesto de fórmula (1) o una sal farmacéuticamente aceptable de este, y un polímero farmacéuticamente aceptable, y (ii) un tensioactivo; y una fase extragranular, donde la fase extragranular comprende al menos uno de los siguientes: un tensioactivo, un disgregante, un deslizante, un lubricante y un relleno. Reivindicación 70: Un método para preparar la dispersión sólida amorfa según una cualquiera de las reivindicaciones 1 a 69, caracterizado porque comprende: mezclar la base libre del Compuesto (I), o la sal farmacéuticamente aceptable de este, con el polímero en una relación de aproximadamente 1:1; agregar uno o más solventes y remover los solventes mediante calentamiento. Reivindicación 71: Una dispersión sólida amorfa caracterizada porque comprende el Compuesto (I) o una sal farmacéuticamente aceptable de este, y un polímero farmacéuticamente aceptable.
ARP220101626A 2021-06-23 2022-06-22 Composiciones farmacéuticas de un inhibidor del receptor del factor de crecimiento epidérmico AR126195A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163214099P 2021-06-23 2021-06-23

Publications (1)

Publication Number Publication Date
AR126195A1 true AR126195A1 (es) 2023-09-27

Family

ID=82608194

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220101626A AR126195A1 (es) 2021-06-23 2022-06-22 Composiciones farmacéuticas de un inhibidor del receptor del factor de crecimiento epidérmico

Country Status (9)

Country Link
US (1) US20240293323A1 (es)
EP (1) EP4358942A1 (es)
JP (1) JP2024525206A (es)
CN (1) CN117835970A (es)
AR (1) AR126195A1 (es)
CA (1) CA3223889A1 (es)
IL (1) IL309447A (es)
TW (1) TW202317120A (es)
WO (1) WO2022271765A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116554150B (zh) * 2022-12-30 2025-12-19 苏州浦合医药科技有限公司 第四代egfr抑制剂
WO2024249660A1 (en) * 2023-05-31 2024-12-05 Amgen Inc. Compositions comprising sotorasib

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100297194A1 (en) * 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter
WO2015152433A1 (en) * 2014-03-31 2015-10-08 Hanmi Pharm. Co., Ltd. Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same
CA3036053A1 (en) * 2016-09-07 2018-03-15 Celgene Corporation Tablet compositions
EP4359400B1 (en) * 2021-06-23 2025-07-02 Blueprint Medicines Corporation Salt and crystal form of an azetidinyl substituted isoquinline acting as epidermal growth factor receptor inhibitor for the treatment of cancer

Also Published As

Publication number Publication date
US20240293323A1 (en) 2024-09-05
WO2022271765A1 (en) 2022-12-29
JP2024525206A (ja) 2024-07-10
IL309447A (en) 2024-02-01
CA3223889A1 (en) 2022-12-29
EP4358942A1 (en) 2024-05-01
TW202317120A (zh) 2023-05-01
CN117835970A (zh) 2024-04-05

Similar Documents

Publication Publication Date Title
PH12022550343A1 (en) Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents
AR126195A1 (es) Composiciones farmacéuticas de un inhibidor del receptor del factor de crecimiento epidérmico
CR20220230A (es) Inhibidores de pequeñas moléculas de mutante g12c de kras
CR20220363A (es) Compuestos tricíclicos sustituidos
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
MX2021011647A (es) Moduladores del receptor x4 de proteina g relacionado con mas y productos y metodos relacionados.
AR056873A1 (es) Derivados de pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina, composiciones farmaceuticas
CR20210426A (es) Compuestos, composiciones y métodos
AR126914A1 (es) Inhibidores de ras novedosos
UY28192A1 (es) Inhibidores de la arn polimerasa dependiente de arn del virus de la hepatitis c y composiciones y tratamientos que los usan.
EA200971081A1 (ru) Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7
AR123018A1 (es) Formulaciones del esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y métodos de uso de este
PE20091403A1 (es) Derivados de carboxamidas n-azabiciclicas y su preparacion
DE60309829D1 (de) Glucocorticoid mimetika, verfahren zu ihrer herstellung, pharmazeutische formulierungen sie enthaltend und verwendungen davon
AR063096A1 (es) Pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina
NO20065613L (no) 3-karbamoyl-2-pyridonderivat.
MX2022004450A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
AR036248A1 (es) Derivados de 2h-piridazin-3-ona, composiciones farmaceuticas que los contienen y un proceso para la preparacion de dichos derivados y el uso de dichos derivados para la preparacion de una composicion farmaceutica
AR062396A1 (es) Uso de derivados de 2,5-dihidroxibenceno para el tratamiento de enfermedades angiogenicas
BR112022003562A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de fibrose de órgãos
UY27685A1 (es) Indolil-urea derivados de tienopiridinas útiles como agentes antiangiogénicos, y procedimientos para su uso
MX2024012470A (es) Inhibidores de cinasas dependientes de ciclina 9 (cdk9)
CL2013003646A1 (es) Compuestos derivados de trans-1-(3s.1r)-6-cloro-3-fenilindan-1-il)-1,2,2-trimetilpiperazina deuterados, con actividad en los receptores 5ht2, d1 y d2; proceso de preparacion; compuesto intermediario; composicion y combinacion farmaceutica; y su uso para el tratamiento de la psicosis, entre otros.
CR20210181A (es) Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa
MX2025002166A (es) Compuestos y metodos para modular her2

Legal Events

Date Code Title Description
FB Suspension of granting procedure